AegirBio AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 0.036 million compared to SEK 0.31 million a year ago. Net loss was SEK 17.94 million compared to SEK 13.43 million a year ago.
For the nine months, sales was SEK 0.093 million compared to SEK 1.7 million a year ago. Net loss was SEK 49.12 million compared to SEK 44.95 million a year ago. Basic loss per share from continuing operations was SEK 2.04 compared to SEK 2.35 a year ago.